Cambridge, United States
Be Biopharma, founded in 2020, is a pioneering player in the Biopharma and Biotechnology sectors. The company's innovative approach is encapsulated in its slogan, "Engineered B cells as medicines," highlighting its commitment to developing novel treatments to significantly enhance patient outcomes.
The organization is at the forefront of creating Engineered B Cell Medicines (BCMs), targeting conditions like Hemophilia B, genetic diseases, cancer, and other severe medical challenges. Based in the United States, Be Biopharma boasts a team of dedicated scientists and experts collaborating to introduce this promising new class of cell therapies.
Their progress is supported by significant investments, most notably a $130.00M Series B round on April 14, 2022. This funding round included prominent investors such as Arch Venture Partners, Atlas Venture, Longwood Fund, RA Capital Management, Alta Partners, Takeda Pharma, and Bristol-Myers Squibb, underscoring the robust confidence in Be Biopharma's pioneering vision.
Autolus Therapeutics
